title: Regional intravenous guanethidine blocks in algodystrophy.
abstract: Five-hundred-thirteen regional intravenous guanethidine blocks were carried out in 125 cases of algodystrophy (118 adults), after failure of other treatments in 120 cases (Group I) and without previous treatments in 5 (Group II). A positive result occurred in 85 cases of Group I (71%) and in the 5 cases of Group II, after 4.5 +/- 1.7 blocks. In Group I the results did not differ significantly between upper (33 cases) and lower (87 cases) limb or in regard to sex, age, duration of disease, nature of previous treatments. The presence of psychic disorders was accompanied by less frequent (p less than 0.02) positive results. The tolerance was satisfactory in 85.6% of cases: 22 moderate side effects authorized a continuation of the blocks, 22 serious ones indicated interruption, especially one case of thrombophlebitis and another one of very transitory acute ischaemia. The risk of intolerance was significantly raised (p less than 0.02) by age. The regional guanethidine blocks seemed to be a good treatment for algodystrophy after failure of other treatments.
authors.affiliation: Department of Rheumatology, Hôpital Militaire BEGIN, Saint-Mande, France.
authors.forename: F
authors.initials: F
authors.lastname: Eulry
authors.forename: D
authors.initials: D
authors.lastname: Lechevalier
authors.forename: B
authors.initials: B
authors.lastname: Pats
authors.forename: C
authors.initials: C
authors.lastname: Alliaume
authors.forename: P
authors.initials: P
authors.lastname: Crozes
authors.forename: P
authors.initials: P
authors.lastname: Vasseur
authors.forename: G
authors.initials: G
authors.lastname: Coutant
authors.forename: D
authors.initials: D
authors.lastname: Felten
authors.forename: S
authors.initials: S
authors.lastname: Pattin
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology; D005069:Evaluation Studies as Topic; D005121:Extremities / Q000098:blood supply; D005260:Female; D006145:Guanethidine / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009407:Nerve Block; D012019:Reflex Sympathetic Dystrophy / Q000503:physiopathology / Q000628:therapy*; D012727:Sex Characteristics
chemical_list: D006145:Guanethidine